An observational study in Children, Acute Pain and Burn Pain, sponsored by Ankara City Hospital Bilkent. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Month to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Ankara City Hospital Bilkent · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Acute Pain with a site in Turkey — 23 open to participants now, 26 under way, none of them phase 3. Acute Pain · Turkey.
Among the 158 studies in Acute Pain with a site in Turkey, this one is the 12th largest by planned enrollment of the 23 observational ones that give a count, is one of 15 that started in 2026, is one of 23 observational ones, reaches primary completion later than 22 of the 25 other live ones, and was the 158th registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →23 of the 158 studies in Acute Pain with a site in Turkey are open now. Recruiting first, the newest first:
Ankara Etlik City Hospital · Sites in Turkey
Ages 18–65
Bursa City Hospital · Sites in Turkey
Ages 18–45 · Women only
Akdeniz University · Sites in Turkey
Ages 6–12 · Healthy volunteers
Harran University · Sites in Turkey
Ages 18–65
Atatürk Chest Diseases and Chest Surgery Training and Research Hospital · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 87 is below the median of 132 across 132 observational studies indexed under Acute Pain.
Median enrollment 80 across the 135 interventional studies, 87 across the 23 observational. Of the 122 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 158 has an industry lead sponsor. The 10 most frequent:
Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.
Ankara City Hospital Bilkent has 5 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07683663Dokuz Eylul UniversityQIPB vs SI-FICB for Postoperative Analgesia After Total Hip Arthroplasty | 2026-12-01 |
| NCT07363096Ankara Etlik City HospitalSingle- Versus Two-Level ESP Block for Analgesia After Lumbar Stabilization Surgery | 2027-01-01 |
| NCT07739277Ankara Etlik City HospitalTransverse vs. Longitudinal Serratus Anterior Plane Block in Breast Surgery | 2027-02-08 |
| NCT07650591Akdeniz UniversityTHE EFFECT OF 'RHYTHMİC SKİN TAPPİNG' AND INTERNAL VİBRATİON APPLİED PROXİMAL TO THE PROCEDURE SİTE ON PAİN AND FEAR PERCEPTİON DURİNG PEDİATRİC PERİPHERAL VENİPUNCTURE | 2027-05 |
| NCT07841951Medipol UniversityTwo Bupivacaine Concentrations for Recto-Intercostal Fascial Plane Block After Laparoscopic Cholecystectomy | 2027-05-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 158 studies in Acute Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, controlled, observational study aims to investigate the relationship between phoenixin (PNX) levels and pain in pediatric burn patients. A total of 87 prepubertal children under 18 years of age will be included and evaluated in three independent groups: 29 children with second-degree burns in the acute burn period and experiencing pain at the time of assessment, 29 children with a history of burn injury at least three months previously who have completed the acute burn and procedural pain period, and 29 age-similar healthy controls without a history of burns or acute pain.
Blood and urine samples will be collected from all participants, and PNX levels will be measured using an enzyme-linked immunosorbent assay (ELISA). Pain intensity will be assessed using age-appropriate validated pain assessment tools, including the Face, Legs, Activity, Cry, Consolability (FLACC) scale and the Visual Analog Scale (VAS), as appropriate. In the burn groups, burn characteristics, including total body surface area (TBSA), will also be recorded.
The study will compare blood and urine PNX levels among the acute burn, chronic burn, and healthy control groups and will evaluate the relationship between PNX levels and clinical pain intensity in children with acute burns. Secondary analyses will examine the relationships between blood and urine PNX levels and their associations with TBSA and demographic and clinical characteristics. The findings are expected to provide preliminary clinical data on the potential role of PNX as a pain-related biological marker in pediatric burn patients.
Phoenixin (PNX) is a neuropeptide with diverse physiological functions, and experimental findings suggest that it may be involved in nociceptive pathways. However, its relationship with clinical pain, particularly acute pain in pediatric burn patients, has not been well established. Pediatric burn pain is a dynamic clinical condition influenced by both the burn injury itself and repeated painful procedures, and objective biological measures that complement clinical pain assessment may contribute to a better understanding of its underlying mechanisms.
This study is designed to investigate the potential relationship between PNX levels and pain in pediatric burn patients by evaluating PNX in both blood and urine. Three clinically distinct populations will be assessed: children in the acute phase of second-degree burn injury with pain at the time of assessment, children with a history of burn injury at least three months previously who are beyond the acute burn and procedural pain period, and age-similar healthy children without acute pain or a history of burns. This design will allow PNX levels observed during acute burn-related pain to be interpreted in comparison with both the post-acute burn period and a population without burn injury or acute pain.
PNX measurements will be evaluated together with age-appropriate clinical pain scores and burn-related characteristics, including total body surface area. Blood and urine PNX levels will also be examined in relation to each other. The study is exploratory and is intended to generate preliminary clinical evidence regarding the potential role of PNX as a pain-related biological marker rather than to establish PNX as a validated diagnostic biomarker for pain.
The study population will consist of pediatric participants prospectively recruited at Ankara Bilkent City Hospital. The acute burn group will include children with acute second-degree burn injuries who are being followed and treated in the pediatric burn intensive care unit. The chronic burn group will consist of children with a previous burn injury, with at least three months elapsed since the burn, who are evaluated during follow-up after the acute phase. The healthy control group will consist of children without a history of burn injury who are evaluated at the same institution. Eligible participants will be consecutively enrolled from the relevant clinical units during the study period. The three groups will constitute the source population for the comparative evaluation of blood and urine phoenixin levels and their relationship with pain and burn-related clinical characteristics.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with second-degree burn injuries who are in the acute burn period and have pain at the time of assessment. Blood and urine samples will be collected for measurement of phoenixin levels, and pain intensity will be assessed using age-appropriate validated pain scales. Burn characteristics, including total body surface area (TBSA), will also be recorded.
Children with a history of burn injury at least three months previously who have completed the acute burn and procedural pain period. Blood and urine samples will be collected for measurement of phoenixin levels.
Age-similar children without a history of burn injury or acute pain. Blood and urine samples will be collected for measurement of phoenixin levels.
Difference in Blood and Urine Phoenixin Levels Among the Study Groups
Blood and urine phoenixin (PNX) concentrations measured by enzyme-linked immunosorbent assay (ELISA) will be compared among the acute burn, chronic burn, and healthy control groups.
Time frame: At the time of study enrollment
Association Between Phoenixin Levels and Pain Intensity in the Acute Burn Group
The association between blood and urine PNX concentrations and clinical pain intensity will be evaluated in children with acute burns. Pain intensity will be assessed using an age-appropriate validated pain assessment scale (FLACC or VAS, as applicable).
Time frame: At the time of study enrollment
Association Between Blood and Urine Phoenixin Levels
The association between blood and urine phoenixin (PNX) concentrations will be evaluated to determine whether PNX levels measured in urine are correlated with those measured in blood.
Time frame: At the time of study enrollment
Association Between Phoenixin Levels and Total Body Surface Area
The association between blood and urine PNX concentrations and total body surface area (TBSA) affected by burn injury will be evaluated in pediatric burn patients.
Time frame: At the time of study enrollment
Association Between Phoenixin Levels and Demographic and Clinical Characteristics
Associations between blood and urine PNX concentrations and demographic and clinical characteristics, including age, sex, and body mass index (BMI), will be evaluated.
Time frame: At the time of study enrollment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.
Of 72 non-industry observational studies under Acute Pain, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 41. This study's planned 7 months is below that.
Counting every sponsor, half of 74 studies reached it within 15 months; a quarter within 5 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara City Hospital Bilkent →